GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Total Receivables

BioNTech SE (BSP:B1NT34) Total Receivables : R$12,502 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Total Receivables?

BioNTech SE's Total Receivables for the quarter that ended in Dec. 2023 was R$12,502 Mil.

BioNTech SE Total Receivables Historical Data

The historical data trend for BioNTech SE's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Total Receivables Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial 92.15 1,041.46 79,118.12 39,707.23 12,501.70

BioNTech SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39,707.23 38,974.16 15,751.65 12,112.73 12,501.70

BioNTech SE Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

BioNTech SE Total Receivables Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BSP:B1NT34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Total Receivables
Comparable Companies
BGNE ALNY MRNA BMRN RPRX LEGN INCY UTHR SRPT TECH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB
Traded in Other Exchanges
BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany BNTX:Austria
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
Website
https://www.biontech.de
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (BSP:B1NT34) Headlines

No Headlines